Get the Stockscreener App
5.67
14.08%
0.70
After Hours:
5.75
0.08
+1.41%
Ataibeckley Inc stock is traded at $5.67, with a volume of 11.47M.
It is up +14.08% in the last 24 hours and up +44.64% over the past month.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
See More
Previous Close:
$4.97
Open:
$4.98
24h Volume:
11.47M
Relative Volume:
1.53
Market Cap:
$2.09B
Revenue:
$3.49M
Net Income/Loss:
$-663.48M
P/E Ratio:
-2.5327
EPS:
-2.2387
Net Cash Flow:
$-115.08M
1W Performance:
+9.25%
1M Performance:
+44.64%
6M Performance:
+52.42%
1Y Performance:
+108.46%
1-Day Range:
$4.97
$5.77
1-Week Range:
$4.81
$5.77
52-Week Range:
$2.58
$6.75
Ataibeckley Inc Stock (ATAI) Company Profile
Name
Ataibeckley Inc
Sector
Industry
Phone
1 929 207 2670
Address
C/O ATAI LIFE SCIENCES US, INC., NEW YORK
Compare ATAI vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
5.67 | 1.83B | 3.49M | -663.48M | -115.08M | -2.2387 |
VRTX
Vertex Pharmaceuticals Inc
|
476.31 | 121.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.12 | 69.52B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
859.43 | 54.49B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
184.97 | 39.11B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.26 | 38.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Deutsche Bank | Buy |
| Jan-20-26 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Jul-29-25 | Initiated | Oppenheimer | Outperform |
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Ataibeckley Inc Stock (ATAI) Latest News
Is AtaiBeckley Inc (ATAI) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Form PRE 14A ATAI Beckley Inc For: 13 July By Investing.com - Investing.com South Africa
What AtaiBeckley (ATAI)'s Full Dosing of VLS-01 Phase 2b Depression Trial Means For Shareholders - simplywall.st
Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says - Proactive Investors
Ataibeckley completes VLS-01 dosing in Phase IIb depression study - MSN
Robert Hershberg, director, sells $496,000 of AtaiBeckley stock - Investing.com UK
What This $496,000 Insider Sale at AtaiBeckley Means Amid Roughly 100% Stock Run - The Motley Fool
Robert Hershberg, director, sells $496,000 of AtaiBeckley stock By Investing.com - Investing.com Nigeria
Form 4 ATAI Beckley Inc For: 9 July By Investing.com - Investing.com Nigeria
ATAI (ATAI) director Hershberg exercises options, sells 100,000 shares under 10b5-1 plan - Stock Titan
AtaiBeckley (ATAI) Stock Looks Stretched With Optimism Already Priced In - simplywall.st
Pα+ Psychedelic Bulletin #227: A Closer Look at Compass’ 6-Month Data; AtaiBeckley Deal Update; ‘Rysanso’ Brand MDMA? - Psychedelic Alpha
Form 144 AtaiBeckley Inc. For: 7 July By Investing.com - Investing.com Nigeria
[144] AtaiBeckley Inc. SEC Filing - Stock Titan
AtaiBeckley Completes VLS-01 Dosing in Phase IIb Depression Study - The Globe and Mail
ATAI Upgraded by Canaccord Genuity -- Price Target Raised to $17 - GuruFocus
AtaiBeckley set to unlock value from positive depression therapy trial results, says Jefferies - Proactive financial news
CCORF Maintains AtaiBeckley(ATAI.US) With Buy Rating, Raises Target Price to $17 - Moomoo
Canaccord raises Atai Life Sciences stock price target to $17 on MDD plans - Investing.com
AtaiBeckley (ATAI) Stock Could Be Overvalued Following Phase 2b Dosing Update - Yahoo Finance
AtaiBeckley | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
AtaiBeckley (ATAI) Draws Takeover Talk From A Major U.S. Drugmaker - Yahoo Finance
Did AtaiBeckley’s (ATAI) FTSE Russell Index Additions and BPL-003 Milestone Just Recast Its Investment Narrative? - webull.com
What AtaiBeckley (ATAI)'s Elumina Last-Patient Dosed Milestone Means For Shareholders - Yahoo Finance
AtaiBeckley (ATAI) Faces Takeover Speculation Amid Stock Fluctua - GuruFocus
AtaiBeckley completes dosing in VLS-01 depression trial - Investing.com UK
AtaiBeckley completes dosing in VLS-01 depression trial By Investing.com - Investing.com Australia
Small cap wrap: Graphene Manufacturing Group, Grey Matter Health, AtaiBeckley… - Proactive financial news
AtaiBeckley finishes dosing patients in Phase 2b depression study - grafa.com
AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder - Investing News Network
AtaiBeckley Announces Last Patient Dosed in Phase 2b Elumina Trial of VLS-01 for Treatment-Resistant Depression; Topline Data Expected in Q4 2026 - Quiver Quantitative
AtaiBeckley ends dosing in VLS-01 depression trial, eyes Phase 3 - Stock Titan
AtaiBeckley completes dosing in Phase 2b depression trial, expects topline data in Q4 - Proactive financial news
ATAIAtaiBeckley Inc Volatility & Greeks - Finviz
AtaiBeckley (ATAI) Advances BPL 003 Into Phase III For Treatment Resistant Depression - Sahm
AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026 - The Globe and Mail
Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026? - The Globe and Mail
AtaiBeckley Reflects a New Push for Rapid-Acting Mental Health Drugs - The Globe and Mail
ATAI Q1 2026 Earnings: Narrower-than-expected loss per share, stock dips 3%Investor Earnings Call - dars.gov.et
Ataibeckley Inc Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ataibeckley Inc Stock (ATAI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HERSHBERG ROBERT | Director |
Jul 07 '26 |
Sale |
4.96 |
100,000 |
496,000 |
100,000 |
0.89%
1.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):